Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Ubiquitin ligases in cancer immunotherapy - balancing antitumor and autoimmunity.
Trends Mol. Med. 25, 428-443 (2019)
Considerable progress has been made in understanding the contribution of E3 ubiquitin ligases to health and disease, including the pathogenesis of immunological disorders. Ubiquitin ligases exert exquisite spatial and temporal control over protein stability and function, and are thus crucial for the regulation of both innate and adaptive immunity. Given that immune responses can be both detrimental (autoimmunity) and beneficial (antitumor immunity), it is vital to understand how ubiquitin ligases maintain immunological homeostasis. Such knowledge could reveal novel mechanisms underlying immune regulation and identify new therapeutic approaches to enhance antitumor immunity and safeguard against autoimmunity.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
E3 Ubiquitin Ligase ; Antitumor Immunity ; Autoimmunity ; Immune Checkpoint; Regulatory T-cells; Nf-kappa-b; Cbl-b; Molecular-mechanisms; Adverse Events; Negative Regulator; Melanoma Patients; Adoptive Therapy; Messenger-rnas; Self-tolerance
ISSN (print) / ISBN
1471-4914
e-ISSN
1471-499X
Journal
Trends in Molecular Medicine
Quellenangaben
Volume: 25,
Issue: 5,
Pages: 428-443
Publisher
Elsevier
Publishing Place
The Boulevard, Langford Lane, Kidlington, Oxford Ox5 1gb, Oxon, England
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Research Unit Apoptosis in Hematopoietic Stem Cells (AHS)